



## Information on the Total Number of Voting Rights (Denominator)

**Liege, Belgium, 29 April 2019 – 17:45 CEST** – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 24 April 2019 for an amount of EUR 84,690 as the result of the exercise of 15 subscription rights (warrants) pursuant to the warrant plan initiated on 2 March 2015.

Following this capital increase, Mithra now has 37,688,995 outstanding shares carrying voting rights (37,664,245 outstanding shares previously).

Therefore, Mithra publishes the updated following information :

- Share capital: EUR 27,591,999.58
- Total number of securities carrying voting rights: 37,688,995 (all ordinary shares)
- Total number of voting rights (= denominator): 37,688,995 (all relating to ordinary shares)
- Number of rights to subscribe securities carrying voting rights not yet issued:
  - Pursuant to the warrant plan of 2 March 2015: 620 warrants giving right to 1,023,000 shares
  - Pursuant to the warrant plan of 5 November 2018 and following the offer of new subscription rights for new members of the Management Team: 1,336,034 warrants giving right to 1,336,034 shares

\*\*\*\*\*

### For more information, please contact:

**Alexandra Deschner (IRO)** : +32 490 58 35 23 - [investorrelations@mithra.com](mailto:investorrelations@mithra.com)

**Maud Vanderthommen (Press)** : +32 473 58 61 04 – [press@mithra.com](mailto:press@mithra.com)

### About Mithra

*Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its three lead development candidates – a fifth generation oral contraceptive Estelle®, the first complete oral treatment for perimenopause PeriNesta™ and next-generation hormone therapy Donesta® - are built on Mithra's unique native estrogen platform, E4 (Estetrol). Mithra also develops and manufactures complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by*

*François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at [www.mithra.com](http://www.mithra.com)*

### **Important information**

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

To receive our press releases by email, please subscribe to our mailing list on [investors.mithra.com](http://investors.mithra.com)